Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Clinica Universidad de Navarra, Universidad de Navarra
Alliance for Clinical Trials in Oncology
Canadian Cancer Trials Group
The Netherlands Cancer Institute
Fudan University
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Tempus AI